Abstract
Introduction: Adalimumab, an inhibitor of tumor necrosis factor-alpha (TNFα), is the only systemic non-corticosteroid agent which has been approved by the US Food and Drug Administration (FDA) for the treatment of non-infectious uveitis. Areas covered: The aim of this review is to summarize the research which demonstrated the effectiveness of adalimumab in the treatment of intraocular inflammation and helped to establish its side effect profile, ultimately leading to its FDA approval. Expert commentary: Adalimumab is a useful second-line agent in the treatment of non-infectious uveitis. While it is only approved in the United States for use in intermediate, posterior, and panuveitis in adults, I find it to be effective in off-label treatment of pediatric uveitis and scleritis as well.
Original language | English (US) |
---|---|
Pages (from-to) | 181-188 |
Number of pages | 8 |
Journal | Expert Review of Clinical Immunology |
Volume | 13 |
Issue number | 3 |
DOIs | |
State | Published - Mar 4 2017 |
Keywords
- Adalimumab
- Behçet
- TNF
- ankylosing spondylitis
- biologic
- juvenile idiopathic arthritis
- sarcoidosis
- tumor necrosis factor-alpha
- uveitis
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology